36 related articles for article (PubMed ID: 34178683)
1. Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis.
Boscolo Bielo L; Repetto M; Crimini E; Belli C; Setola E; Parma G; Fusco N; Barberis M; Guerini Rocco E; Marra A; Colombo N; Curigliano G
Oncologist; 2024 May; ():. PubMed ID: 38716772
[TBL] [Abstract][Full Text] [Related]
2. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.
McNamara B; Harold J; Manavella D; Bellone S; Mutlu L; Hartwich TMP; Zipponi M; Yang-Hartwich Y; Demirkiran C; Verzosa MSZ; Yang K; Choi J; Dong W; Buza N; Hui P; Altwerger G; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Burton EA; Inagaki H; Albers A; Zhang C; Bollag G; Schlessinger J; Santin AD
Gynecol Oncol; 2023 May; 172():65-71. PubMed ID: 36958197
[TBL] [Abstract][Full Text] [Related]
3. Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma.
Kodama M; Shimura H; Tien JC; Newberg JY; Kodama T; Wei Z; Rangel R; Yoshihara K; Kuruma A; Nakae A; Hashimoto K; Sawada K; Kimura T; Jenkins NA; Copeland NG
Cancer Res; 2021 Nov; 81(21):5413-5424. PubMed ID: 34475109
[TBL] [Abstract][Full Text] [Related]
4. Integrated Whole-Exome and Transcriptome Sequencing Indicated Dysregulation of Cholesterol Metabolism in Eyelid Sebaceous Gland Carcinoma.
Wang Y; Li J; Hao P; Li J; Han R; Lin J; Li X
Transl Vis Sci Technol; 2023 Feb; 12(2):4. PubMed ID: 36735267
[TBL] [Abstract][Full Text] [Related]
5. Genomic Characterization by Whole-Exome Sequencing of Hypermobility Spectrum Disorder.
Alanis-Funes GJ; Lira-Albarrán S; Hernández-Pérez J; Garza-Elizondo MA; Ortíz-López R; Elizondo CV; Rojas-Martinez A; Chávez-Santoscoy RA; Rangel-Escareño C
Genes (Basel); 2022 Jul; 13(7):. PubMed ID: 35886052
[TBL] [Abstract][Full Text] [Related]
6. A Study of the Genomic Variations Associated with Autistic Spectrum Disorders in a Russian Cohort of Patients Using Whole-Exome Sequencing.
Gibitova EA; Dobrynin PV; Pomerantseva EA; Musatova EV; Kostareva A; Evsyukov I; Rychkov SY; Zhukova OV; Naumova OY; Grigorenko EL
Genes (Basel); 2022 May; 13(5):. PubMed ID: 35627305
[TBL] [Abstract][Full Text] [Related]
7.
Nassif EF; Auclin E; Bahleda R; Honoré C; Mir O; Dumont S; Mery B; Hodroj K; Brahmi M; Trédan O; Ray-Coquard I; Blay JY; Massard C; Le Cesne A; Dufresne A
Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34282771
[TBL] [Abstract][Full Text] [Related]
8. A bibliometric analysis of literatures on uterine leiomyosarcoma in the last 20 years.
Huang J; Chen Y; Li Z; Chen M; Huang D; Zhu P; Han X; Zheng Y; Chen X; Yu Z
Front Oncol; 2024; 14():1343533. PubMed ID: 38410101
[TBL] [Abstract][Full Text] [Related]
9. COTE1 Facilitates Intrahepatic Cholangiocarcinoma Progression via Beclin1-Dependent Autophagy Inhibition.
Zhang H; Chen S; Xu S; Li X
Biomed Res Int; 2023; 2023():5491682. PubMed ID: 37780485
[TBL] [Abstract][Full Text] [Related]
10. Molecular Insights in Uterine Leiomyosarcoma: A Systematic Review.
Sparić R; Andjić M; Babović I; Nejković L; Mitrović M; Štulić J; Pupovac M; Tinelli A
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077127
[TBL] [Abstract][Full Text] [Related]
11. Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways.
Cuppens T; Moisse M; Depreeuw J; Annibali D; Colas E; Gil-Moreno A; Huvila J; Carpén O; Zikán M; Matias-Guiu X; Moerman P; Croce S; Lambrechts D; Amant F
Int J Cancer; 2018 Mar; 142(6):1230-1243. PubMed ID: 29063609
[TBL] [Abstract][Full Text] [Related]
12. Analysis of molecular cytogenetic alterations in uterine leiomyosarcoma by array-based comparative genomic hybridization.
Raish M; Khurshid M; Ansari MA; Chaturvedi PK; Bae SM; Kim JH; Park EK; Park DC; Ahn WS
J Cancer Res Clin Oncol; 2012 Jul; 138(7):1173-86. PubMed ID: 22419440
[TBL] [Abstract][Full Text] [Related]
13. Status of the Current Treatment Options and Potential Future Targets in Uterine Leiomyosarcoma: A Review.
Asano H; Isoe T; Ito YM; Nishimoto N; Watanabe Y; Yokoshiki S; Watari H
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267488
[TBL] [Abstract][Full Text] [Related]
14. Interrogating the Genomic Landscape of Uterine Leiomyosarcoma: A Potential for Patient Benefit.
Dall GV; Hamilton A; Ratnayake G; Scott C; Barker H
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326717
[TBL] [Abstract][Full Text] [Related]
15. Identification of Somatic Genetic Alterations Using Whole-Exome Sequencing of Uterine Leiomyosarcoma Tumors.
Chen L; Li J; Wu X; Zheng Z
Front Oncol; 2021; 11():687899. PubMed ID: 34178683
[TBL] [Abstract][Full Text] [Related]
16. Integrated mutational landscape analysis of uterine leiomyosarcomas.
Choi J; Manzano A; Dong W; Bellone S; Bonazzoli E; Zammataro L; Yao X; Deshpande A; Zaidi S; Guglielmi A; Gnutti B; Nagarkatti N; Tymon-Rosario JR; Harold J; Mauricio D; Zeybek B; Menderes G; Altwerger G; Jeong K; Zhao S; Buza N; Hui P; Ravaggi A; Bignotti E; Romani C; Todeschini P; Zanotti L; Odicino F; Pecorelli S; Ardighieri L; Bilguvar K; Quick CM; Silasi DA; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Imielinski M; Schwartz PE; Alexandrov LB; Lifton RP; Schlessinger J; Santin AD
Proc Natl Acad Sci U S A; 2021 Apr; 118(15):. PubMed ID: 33876771
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
